Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells

被引:5
|
作者
Nicoletti, MI
Myers, TG
Fojo, T
Blagosklonny, MV
机构
[1] NCI, Med Branch, NIH, Bethesda, MD 20892 USA
[2] NCI, Dev Therapeut Program, NIH, Bethesda, MD 20892 USA
关键词
p53; MDR-1; drug resistance;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The notion that wt p53 downregulates MDR-1 links p53 mutations to multidrug resistant phenotype. Alternatively, it has been envisioned that wt p53 protects cells against DNA damaging drugs by inducing MDR-1. Opposing conclusions on the relationship between MDR-1 and p53 have been predominantly based on the effects of p53 on MDR-1 promoter-constructs. We found that introduction of wt p53 slightly induced MDR-1 mRNA in three cell lines having endogenous mt p53. Wt p53-mediated induction of endogenous MDR-1 may represent a rudiment of cellular protection against toxic compounds earlier in evolution. Marked induction of p21(WAF1/CIP1) (p21) mRNA was observed in all cell lines; and lower levels of wt p53 were required to induce p21 than MDR-1. Pgp was undetectable and wt p53 did not increase resistance to an MDR-1 substrate, suggesting the changes in MDR-1 mRNA may be functionally insignificant. Unlike endogenous MDR-1, the expression of an MDR-1 promoter (-434/+147 fragment) - luciferase construct was unchanged or even inhibited by wt p53 that may be secondary to wt p53-mediated cytotoxicity. Thus, partial promoter constructs may not accurately represent endogenous MDR-1.
引用
收藏
页码:375 / 381
页数:7
相关论文
共 50 条
  • [21] Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53
    Gjerset, RA
    Turla, ST
    Sobol, RE
    Scalise, JJ
    Mercola, D
    Collins, H
    Hopkins, PJ
    MOLECULAR CARCINOGENESIS, 1995, 14 (04) : 275 - 285
  • [22] Gene therapy of malignant gliomas: Adenovirus-mediated wild-type p53 expression induces widespread apoptosis of human glioma cells independently of endogenous p53 status
    Li, HW
    Lochmuller, H
    Seth, P
    Karpati, G
    Nalbantoglu, J
    NEUROLOGY, 1997, 48 (03) : 1026 - 1026
  • [23] Role of p53 in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53
    Ji, Wansheng
    Ma, Jingrong
    Zhang, Hongmei
    Zhong, Hua
    Li, Lei
    Ding, Na
    Jiao, Jianxin
    Gao, Zhixing
    MOLECULAR MEDICINE REPORTS, 2015, 12 (01) : 691 - 695
  • [24] Transduction of a wild-type p53 gene into human malignant melanoma cells
    Hakim, AA
    CANCER GENE THERAPY, 2001, 8 : S8 - S8
  • [25] Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells
    Schlamp, CL
    Poulsen, GL
    Nork, TM
    Nickells, RW
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (20) : 1530 - 1536
  • [26] Modulation of wild-type p53 activity in cancer cells and in the tumor microenvironment
    Oren, Moshe
    Arandkar, Sharathchandra
    Benor, Gal
    Furth, Noa
    Aylon, Yael
    Domany, Eytan
    CANCER RESEARCH, 2019, 79 (13)
  • [27] Wild-type p53 in cancer cells: When a guardian turns into a blackguard
    Kim, Ella
    Giese, Alf
    Deppert, Wolfgang
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (01) : 11 - 20
  • [28] Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells
    Meplan, Catherine
    Mann, Kris
    Hainautt, Pierre
    Journal of Biological Chemistry, 274 (44): : 31663 - 31670
  • [29] Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells
    Méplan, C
    Mann, K
    Hainaut, P
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (44) : 31663 - 31670
  • [30] GROWTH SUPPRESSION MEDIATED BY TRANSFECTION OF P53 IN HUT292DM HUMAN LUNG-CANCER CELLS EXPRESSING ENDOGENOUS WILD-TYPE P53 PROTEIN
    CAJOT, JF
    ANDERSON, MJ
    LEHMAN, TA
    SHAPIRO, H
    BRIGGS, AA
    STANBRIDGE, EJ
    CANCER RESEARCH, 1992, 52 (24) : 6956 - 6960